Objective To explore the impact of clinical efficacy , blood rheology and inflammation of Mailuoshutong particles rivaroxaban in patients with deep venous thrombosis .Methods From June 2014 to June 2016 in Sichuan province Mianyang Central Hospital , 120 cases of patients with deep venous thrombosis as the research object were enrolled , according to randomly method, they were divided into observation group ( n =60) and control group ( n =60), 2 groups treated with absolute bed rest , limb elevation , braking , and the control group was given oral treatment of rivaroxaban .In the observation group were given Mailuoshutong particles of 7 d, after treatment, 2 groups of patients’ clinical curative effect, respectively before and after treatment were observed , and clinical symptoms, blood rheology and serum interleukin 6 (IL-6), high sensi-tive C reactive protein (hs-CRP) were compared.Results The total efficiency of the observation group was significantly high-er than the control group (96.67% vs.83.33%,χ2 =5.926, P =0.015), but no significant difference in complications (3.33%vs.5.00%,χ2 =0.209, P =0.648).After treatment, the observation group pain score, limb circumference, pig-mentation score, ulcer area significantly decreased compared to the control group ( t =4.865, t =10.263, t =3.034, t =12.474, P =0.000); plasma D dimer (D-D), fibrinogen (FIB), plasma viscosity (CP), erythrocyte aggregation index (RCAI) level significantly decreased compared to the control group ( t =21.278, t =22.585, t =3.387, t =8.735, P =0.000);serum IL-6, hs-CRP levels significantly decreased compared to the control group ( t =18.320, t =7.241, P =0.000).Conclusion Mailuoshutong particles combined with rivaroxaban can effectively improve the patients with deep ve -nous thrombosis clinical treatment effect , improve clinical symptoms and blood viscosity , and can effectively reduce the in-flammatory reaction , is conducive to the prognosis of patients .%目的：观察脉络疏通颗粒联合利伐沙班对下肢深静脉血栓患者临床疗效、血液流变学指标及炎性因子的影响。方法选取2014年6月—2016年6月四川省绵阳市中心医院血管外科收治下肢深静脉血栓患者120例作为研究对象，根据随机数字表法将患者分为观察组（ n ＝60）及对照组（ n ＝60），2组绝对卧床休息、患肢抬高、制动，对照组同时给予利伐沙班口服治疗，观察组在对照组基础上给予脉络疏通颗粒口服治疗，治疗7d后比较2组患者临床治疗效果，分别于治疗前及治疗后观察2组临床症状、血液流变学指标及血清白细胞介素－6（IL－6）、超敏C反应蛋白（hs－CRP）水平。结果观察组总有效率显著高于对照组（96．67％vs．83．33％，χ2＝5．926， P ＝0．015），而并发症比较差异无统计学意义（3．33％vs．5．00％，χ2＝0．209， P ＝0．648）。治疗后观察组肢体周径、疼痛评分、色素沉着评分、溃疡面积较对照组显著下降（ t ＝4．865、10．263、3．034、12．474， P均＝0．000）；血浆D－二聚体（D－D）、纤维蛋白原（FIB）、血浆黏度（CP）、红细胞聚集指数（RCAI）水平亦较对照组显著下降（ t ＝21．278、22．585、3．387、8．735， P均＝0．000）；血清IL－6、hs－CRP水平较对照组显著下降（ t ＝18．320、7．241， P均＝0．000）。结论脉络疏通颗粒联合利伐沙班能有效提高下肢深静脉血栓患者临床治疗效果，改善患者临床症状及血液黏稠度，并能有效降低炎性反应，有利于患者预后。
展开▼
